Novartis Drug Approved for Symptomatic Dermographism

The U.S. FDA has approved Novartis's Rhapsido (remibrutinib), an oral BTKi, as the first specific treatment for adults with symptomatic dermographism (SD) not adequately controlled by H1 antihistamines. This approval offers a new therapeutic option for individuals experiencing chronic hives and itching triggered by skin friction, addressing a previously unmet medical need for this condition.